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Abstract: Since the American Heart Association’s recommendation for familial screening of adults
with congenital heart disease for bicuspid aortic valve, similar recommendations for other left-sided
heart defects, such as hypoplastic left heart syndrome (HLHS), have been proposed. However,
defining at-risk populations for these heart defects based on genetics is less straightforward due to the
wide variability of inheritance patterns and non-genetic influences such as environmental and lifestyle
factors. We discuss whether there is sufficient evidence to standardize echocardiographic screening
for first-degree relatives of children diagnosed with HLHS. Due to variations in the inclusion of
cardiac anomalies linked to HLHS and the identification of asymptomatic individuals with cardiac
malformations, published studies are open to interpretation. We conclude that familial aggregation
of obstructive left-sided congenital heart lesions in families with history of HLHS is not supported
and recommend that additional screening should adopt a more conservative definition of what
truly constitutes this heart defect. More thorough consideration is needed before embracing familial
screening recommendations of families of patients with HLHS, since this could inflict serious costs
on healthcare infrastructure and further burden affected families both emotionally and financially.
Keywords: familial screening; congenital heart disease; hypoplastic left heart disease; cost-effectiveness;
bicuspid aortic valve; familial aggregation
1. Introduction
Screening protocols for at-risk populations improve the outcomes of patients with diseases that
are asymptomatic by detecting them before they progress far enough to be imminently life-threatening
and facilitating their treatment. The challenge in balancing this potentially life-saving tool with
cost-effectiveness, while avoiding frequent misdiagnosis, lies in correctly identifying such populations.
Likewise, the heritability and associated pathologies of each disease must be taken into consideration
when making screening recommendations. In 2008, the American Heart Association recommended
familial screening for bicuspid aortic valve (BAV) in their clinical practice guidelines for adults with
congenital heart disease (CHD) [1]. Since then, several studies have made similar recommendations
for other left-sided heart defects, in particular, hypoplastic left heart syndrome (HLHS) and coarctation
of the aorta (CoA) [2–5]. Understanding the existing data for familial aggregation of these diseases
using the tools available for evaluating the efficacy of a screening recommendation is important to
determine whether familial screening should be extended to other left-sided heart lesions.
2. Methods
A literature review was performed to determine the methodology used in investigating familial
clustering of cardiac diseases. We focused on studies concerning cardiac defects because the cost
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and limitations associated with image-based screening are not necessarily the same for familial
clustering/screening protocols for other diseases. The population-based studies used the following
basic principles—recruit a cohort of patients with the disease of interest (index cases), construct
a pedigree based on family history of first- and second-degree relatives, and lastly, screen first-degree
relatives for undiagnosed defects similar to the disease of interest. Studies varied in strength depending
on alterations in their methodology, such as including a blind reviewer for validation of image-based
diagnoses [6,7].
3. Results
3.1. Bicuspid Aortic Valve Studies
Familial aggregation of BAV was first noticed in 1977 by Gale et al. [8]. Later, Huntington et al.
recruited 210 first-degree relatives of 30 patients with BAV to see if the isolated reports of families
with multiple cases of BAV held true in a larger population [9]. Of the 186 subjects they screened
by echocardiography, 17 cases of BAV were found. To strengthen the case for utilizing a familial
BAV screening protocol, studies have analyzed the heritability of BAV in family populations and
analyzed the cost-effectiveness of such screening. To determine the heritability of BAV compared to
various cardiovascular malformations (CVM), Cripe et al. screened first-degree relatives of 50 patients
with BAV [4]. Using “maximum-likelihood-based variance decomposition extended to dichotomous
traits”, they estimated the heritability of BAV in their sample to be 89% and concluded that the
suggestion for screening first-degree relatives of those with BAV was warranted [4]. McBride et al.,
who examined 124 families (351 individuals) with an index case of left ventricular outflow tract
malformations, identified CVM in approximately 9% of relatives, 5% of which were BAV cases [10].
In their study, the relative risk for first degree relatives was calculated to be 36.9 with a heritability of
0.71–0.90, prompting them to recommended screening of asymptomatic relatives. Similarly, a large
study by Lewin et al. screened 282 asymptomatic first-degree relatives of children with congenital
aortic valve stenosis, HLHS, and CoA; their findings led them to recommend echocardiographic
evaluation for asymptomatic parents and siblings of individuals with left ventricular outflow tract
lesions for cardiovascular anomalies, particularly BAV [3].
The cost-effectiveness of screening siblings of BAV patients has been evaluated by Hales et al. [11].
In order to estimate the cost of identifying and preventing an aortic dissection in a sibling of
a patient with BAV (based on the assumption that the newly identified subject would get a limited
echocardiography every two years), the authors considered: the cost of undergoing an echocardiogram,
the probability of detecting a cardiovascular malformation, the probability of experiencing an
aortic dissection, life expectancy, and mortality from dissection. They deemed their estimate of
$363,911/per individual acceptable, especially when compared to other screening protocols, such as
universal echocardiographic screening for CHD [12] or 2D echocardiographic screening of young
adult athletes [13]. Collectively, these studies indicating the aggregation and heritability of BAV,
as well as the cost-effectiveness of screening first-degree relatives, were overwhelming enough to
prompt the American Heart Association and the American College of Cardiology [14] to recommend
that all physicians adopt the practice [1]. As in the realm of device and drug approval, however,
it would be prudent to test this recommendation in the real world, where the selection of the index
case may pose certain challenges. A clear example is the difficulty of diagnosing BAV in a newborn;
such ascertainments, if biased, could impact frequency counts, as described in the Cripe study [4].
3.2. Screening for Hypoplastic Left Heart Syndrome
Hypoplastic left heart syndrome is another left-sided heart defect with complex genetic
influences [15–18]. Some evidence suggests that first-degree relatives of patients with HLHS have
a higher incidence of BAV (12%) [7] compared with the general population (1–2%) [19]. This has raised
the question of whether HLHS is another CVM for which familial screening should be implemented,
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similar to BAV, due to the significant morbidity and mortality associated with HLHS [20–23].
Studies investigating the heritability of HLHS typically recruit HLHS probands and their first-
and second-degree relatives to participate in screening studies with the goal of determining the
familial clustering and heritability of this CHD [3,6,15]. Cascade screening is used to systematically
identify close relatives of index cases to determine if the relatives may be carriers or unknowingly
be affected with a particular disease. In recent years, cascade screening based on genetic testing has
been implemented for several diseases, including familial hypercholesterolemia [24,25] and fragile X
syndrome [26], for which it is highly beneficial and cost-effective. Amongst CHD, based on current
diagnostic strategies, our study suggests that while cascade screening may be an attractive option in
the case of BAV, HLHS does not meet the criteria for this strategy given its complicated inheritance.
HLHS does not follow simple Mendelian genetics, but rather exhibits “complex inheritance”,
with contributions from both genetic [18,27,28] and environmental risk factors [6,29,30]. Overall,
while the results of these studies support the notion of familial clustering of HLHS, the evidence is not
as overwhelming as for BAV.
One of the earliest published population screening studies focusing on HLHS was conducted in
1989 by Brenner et al. on data collected in the Baltimore-Washington Infant Study [7]. These investigators
recruited first-degree relatives of 14 patients diagnosed with HLHS as defined by “ . . . aortic atresia
and mitral stenosis-atresia with hypoplasia of the left ventricle”. Of the 41 first-degree relatives studied,
5 (12%) had a left ventricular outflow tract abnormality. The report concluded that the identification
of the affected first-degree relatives could be a coincidence due to a selection bias resulting from the
selection of probands with severe rather than mild left-sided heart defects. Alternatively, the CVM
identified in the relatives could be caused by a defect in a common gene or set of genes. Regardless
of the case, they reasoned that the sample size of their cohort was insufficient to reach a definitive
conclusion regarding familial clustering of HLHS.
Subsequently, a study published eight years later, titled “Hypoplastic Left Heart Syndrome is
Heritable”, recruited 38 patients with HLHS and 193 of their family members (126 first-degree relatives)
and screened them for CVM [15]. They identified CVM in 24% of the relatives, including HLHS, BAV,
CoA, ventricular septal defects (VSD), aortic root dilatation, and left superior vena cava. The incidence
of CVM in the first-degree relatives was 23 of 126 (18.3%); 12 of the 126 had isolated BAV (9.5%); one of
the 126 had CoA (0.8%); and four out of the 126 (3.2%) had HLHS, two of whom were siblings from
the same family (i.e., each proband counted as a first-degree relative for the other). Using a liberal
normal population incidence estimate of 0.08%, they determined the heritability to be as high as 0.99,
and noted that the pattern of inheritance was likely complex.
3.3. Cardiovascular Malformations Associated with HLHS
Evidence of heritability can vary across studies based on which CVM are included in the analyses.
For instance, a study by Kelle et al. [2] was much less stringent in the inclusion of what constituted
a CVM related to HLHS, and unlike the studies that support BAV familial screening, it did not show
a high incidence of a one-to-one association between a disease in a patient and that same disease
in relatives. The etiology of natural cardiac anatomical variants, such as patent ductus arteriosus
(PDA), anomalous aortic origin of coronary arteries, or patent foramen ovale (PFO), does not involve
a pathological error in cardiac formation, but rather may represent a spectrum of normal developmental
variations. Moreover, the prevalence and incidence of these and other malformations in the general
population need to be considered to contextualize such conclusions. Among these, PFO is found in
15–25% of healthy adults, while persistence of congenital anomalies such as left-sided superior vena
cava (considered the most common central venous anomaly) has an incidence of 0.1–0.3% in the general
population and 2.1–5% in patients with CHD [31–33]. The inclusion of diagnoses of left superior vena
cava anomalies, PFO, and aortic root dilatation alongside cardiac defects such as VSD, tetralogy of
Fallot, and CoA may be inappropriate and lead to incorrect conclusions and erroneous heritability
calculations. Table 1 shows the expected numbers, for example, in a study with a small sample size,
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as reported by Kelle et al. [2], of how many common cardiovascular anomalies one would diagnose in
the general population simply by chance. Inclusion of these common CVM would, therefore, lead to
a measurement bias in a small sample size, especially if the pathophysiological mechanism is unclear.
Table 1. Prevalence of common cardiovascular abnormalities in the general population and the
expected number of CVM diagnosed by chance in a study with a small sample size. Abbreviations:
ASD = atrial septal defect; PAPVR = partial anomalous pulmonary venous return; PDA = patent ductus





Expected Number (N = 152)
Kelle et al. [2]
PFO 148/5581 (25.6%) [34] 40 (26.31%)
PDA 35/56,109 (0.06%) [35] 1 (0.66%)
ASD 523/398,140 (0.13%) [36] 1 (0.66%)
PLSVC 5/5000 (0.1%) [37] 1 (0.66%)
PAPVR 47/45,538 (0.1%) [38] 1 (0.66%)
Similarly, partial anomalous pulmonary venous return (PAPVR) is a common CVM reported
at high frequency among the general population (Table 1). Ho et al. retrospectively identified
49 asymptomatic adult patients with incidental PAPVR findings from 45,538 contrast-enhanced
computed tomography examinations of the chest performed over an eight-year period, reporting
a prevalence of at least 0.1% among the general population [38]. Likewise, Hughes et al. reported an
incidence of 0.7% of anomalous pulmonary veins in 208 cadavers examined [39]. Another common
CVM included in some studies is mitral valve prolapse (MVP) with mitral regurgitation. The prevalence
of MVP was reported as 2.4% in adults in the Framingham Heart Study among 3491 subjects [40],
and 0.7% in a population of 2072 healthy teenagers [41]. The presence of MVP in the aforementioned
study populations clearly shows that this CVM occurs at a significant rate in the general population,
and could therefore be expected to occur by chance among a small study population. Thus, without
a clear pathophysiological relationship, considering MVP as a CVM finding when screening first-degree
relatives of individuals with HLHS could lead to measurement bias.
Three recent studies that have made family screening recommendations for HLHS vary in their
definition of CVM linked to HLHS. In contrast to the studies supporting BAV screening, which were
based on a one-to-one association of BAV and family members, definitions of HLHS are linked to
four or more other CVMs. In the first study, Kelle et al. analyzed the prevalence of CVMs among
152 first-degree relatives of 52 patients diagnosed with HLHS [2]. Based on an 11% incidence of CVM
in the study population, the authors suggest that echocardiographic screening should be standard for
first-degree relatives of children diagnosed with HLHS. The CVMs included in the list of diagnoses
were anomalous aortic origin of the right coronary artery, BAV, bicuspid pulmonary valve, CoA, dilated
ascending aorta with normal aortic valve, dilated aortic root with accessory mitral chord tissue, mitral
valve prolapse with mitral regurgitation, PAPVR, papillary fibroelastoma, PDA, and VSD. A second
study by Loffredo et al. reported a 19.3% incidence of CVM in a population of 135 first-degree relatives
of patients diagnosed with HLHS [6]. Although this study limited HLHS-related CVM to atrial septal
defects (ASD), BAV, PDA, VSD, and tetralogy of Fallot, it did not clearly state whether they were certain
that some of the ASD were not PFO diagnoses. Moreover, this study did not associate an age, gender,
or history of intervention with the first-degree relatives diagnosed with ASD. As a result, no inferences
can be made about the size of the defects, which could potentially allow one to differentiate an ASD
from a PFO. In a third study by Brenner et al., the anomalies considered as CVMs related to HLHS
were BAV and mild aortic stenosis, with an incidence of 12.2% in a population of 41 relatives [7].
Furthermore, conditions such as aortic root dilatation are associated with a number of disease
mechanisms including hemodynamic and blood pressure imbalances, as reported in cohorts of the
Strong Heart Study [42] and the Framingham Heart Study [43]. The latter analysis was a longitudinal
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study over a period of 16 years which demonstrated that aortic root remodeling in mid to late
adulthood is common using serial echocardiograms. Their results show that a decade increase in age
was associated with a larger aortic root and cardiac remodeling [44]. In the Coronary Artery Risk
Development in Young Adults Study, aortic root diameter in healthy young adults (ages 18–30 years)
studied using echocardiography over a 20-year time period was found to be modified by smoking,
hypertension, and body weight gain [45]. These studies show that environmental and lifestyle factors
which can influence the course of certain CVM need to be recognized.
3.4. The Cost of Screening
The data regarding familial aggregation of left-sided heart defects besides BAV does not
convincingly indicate whether familial screening for defects such as HLHS or CoA should or
should not be instituted. As discussed above, population screening studies, as well as cascade
familial screening [24,26] can identify asymptomatic defects; however, if improperly implemented,
the costs may outweigh any benefits. Based on the average cost of an echocardiogram (approximately
$700), if 10–15% of first-degree relatives have a ‘CVM’ lesion (i.e., one would have to perform an
echocardiogram evaluation of 10–15 individuals to find one CVM), the cost of identifying the CVM
would be approximately $7000–$11,000 per year for that single relative. Using the prevalence of
HLHS, 1 in 4344 births [46], and assuming four million births per year in the United States, there are
approximately 800 anticipated HLHS births per year. If each one of these probands led to familial
screening, it would cost approximately $5.6 million to identify a malformation in 800 relatives
(assuming screening of 10 relatives). The question is whether this is a reasonable cost for identifying
common congenital anomalies that are asymptomatic or associated with other CVM—such as left
superior vena cava [47], PFO, or PDA [48]—among the general population? If the goal is to identify
serious CVM with potential life-long consequences, then studies examining the efficacy of familial
screening should be carried out with rigorous inclusion criteria.
4. Conclusions
In order to prevent unnecessary financial and emotional burden, a more thorough consideration
and investigation into the causal mechanisms of CHD is needed before embracing the screening
recommendations proposed for families of patients with select CHD such as HLHS. Continued
pragmatic trials are necessary to evaluate recommendations made based on small single-center studies.
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